Since altered copeptin levels were determined in many emergent clinical situations, copeptin is suggested to be a valuable prognostic biomarker in those situations including pulmonary diseases, heart disease, stroke, shock and traumatic brain injury. This evidence concerns the gene AVP and stroke disorder.